Seattle Genetics' has put cancer squarely in the sites of its targeted treatment technology. Will the pipeline powered by this breakthrough science propel its stock higher? Mad Money's Jim Cramer interviews the CEO.
Published 2014-03-20 · Watch on YouTube ↗ Availability and playback restrictions are controlled by the original channel.
02:03
